Curr Drug Deliv:新型生物活性玻璃支架可有效恢复颅骨缺损

2019-06-15 不详 网络

在骨组织工程领域,对具有高血管生成能力和成骨能力的生物医学材料越来越感兴趣。在各种成骨材料中,生物活性硼硅酸盐和硼酸盐玻璃支架具有合适的降解速率和机械强度,因而引起了许多学者的兴趣和关注。在这项研究中,我们使用模板法制备了由硼硅酸盐2B6Sr组成的生物活性玻璃支架,并掺入了具有良好血管生成能力的小分子血管生成药物二甲基肟基甘氨酸(DMOG),以改善骨再生。体外研究表明,多孔硼硅酸盐生物活性玻璃支架

在骨组织工程领域,对具有高血管生成能力和成骨能力的生物医学材料越来越感兴趣。在各种成骨材料中,生物活性硼硅酸盐和硼酸盐玻璃支架具有合适的降解速率和机械强度,因而引起了许多学者的兴趣和关注。

在这项研究中,我们使用模板法制备了由硼硅酸盐2B6Sr组成的生物活性玻璃支架,并掺入了具有良好血管生成能力的小分子血管生成药物二甲基肟基甘氨酸(DMOG),以改善骨再生。

体外研究表明,多孔硼硅酸盐生物活性玻璃支架释放缓慢,稳定的DMOG,并刺激人骨髓基质细胞hBMSCs的增殖和成骨分化。体内研究表明,硼硅酸盐生物活性玻璃支架可显着促进大鼠颅骨缺损中的新骨形成和新生血管形成。

综上所述,这些结果表明,掺入DMOG的生物活性玻璃支架是一种具有优良血管生成-成骨能力的成功化合物,具有良好的临床应用前景。

原始出处:

Jin X, Han D, et al., Dimethyloxallyl glycine-incorporated borosilicate bioactive glass scaffolds for improving angiogenesis and osteogenesis in critical-sized calvarial defects. Curr Drug Deliv. 2019 Jun 10. doi: 10.2174/1567201816666190611105205. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005192, encodeId=36e22005192f6, content=<a href='/topic/show?id=af6e6938483' target=_blank style='color:#2F92EE;'>#生物活性玻璃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69384, encryptionId=af6e6938483, topicName=生物活性玻璃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 26 07:31:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862335, encodeId=cdc21862335ba, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Jun 30 23:31:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419319, encodeId=01c6141931910, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Mon Jun 17 11:31:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005192, encodeId=36e22005192f6, content=<a href='/topic/show?id=af6e6938483' target=_blank style='color:#2F92EE;'>#生物活性玻璃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69384, encryptionId=af6e6938483, topicName=生物活性玻璃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 26 07:31:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862335, encodeId=cdc21862335ba, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Jun 30 23:31:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419319, encodeId=01c6141931910, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Mon Jun 17 11:31:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2019-06-30 wangbingxhy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005192, encodeId=36e22005192f6, content=<a href='/topic/show?id=af6e6938483' target=_blank style='color:#2F92EE;'>#生物活性玻璃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69384, encryptionId=af6e6938483, topicName=生物活性玻璃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 26 07:31:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862335, encodeId=cdc21862335ba, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Jun 30 23:31:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419319, encodeId=01c6141931910, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Mon Jun 17 11:31:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2019-06-17 lfcmxl